These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32942864)

  • 1. [Dyslipidemia in patients with chronic kidney disease: etiology and management].
    Dušejovská M; Vecka M; Rychlík I; Žák A
    Vnitr Lek; 2020; 66(5):275-281. PubMed ID: 32942864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dyslipidemia in Patients with Kidney Disease.
    Thobani A; Jacobson TA
    Cardiol Clin; 2021 Aug; 39(3):353-363. PubMed ID: 34247749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment.
    Tsimihodimos V; Dounousi E; Siamopoulos KC
    Am J Nephrol; 2008; 28(6):958-73. PubMed ID: 18612199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyslipidemia and stroke in patients with chronic kidney disease].
    Kes P; Bašić-Kes V; Furic-Cunko V; Mesar I; Bašić-Jukić N
    Acta Med Croatica; 2014 Apr; 68(2):141-9. PubMed ID: 26012152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dyslipidemia in Dialysis Patients.
    Qunibi WY
    Semin Dial; 2015; 28(4):345-53. PubMed ID: 25855389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 in chronic kidney disease.
    Pavlakou P; Liberopoulos E; Dounousi E; Elisaf M
    Int Urol Nephrol; 2017 Jun; 49(6):1015-1024. PubMed ID: 28084558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etiology and management of dyslipidemia in children with chronic kidney disease and end-stage renal disease.
    Khurana M; Silverstein DM
    Pediatr Nephrol; 2015 Dec; 30(12):2073-84. PubMed ID: 25801207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of quality of sleep between patients with chronic kidney disease not on hemodialysis and end-stage renal disease on hemodialysis in a developing country.
    Shafi ST; Shafi T
    Ren Fail; 2017 Nov; 39(1):623-628. PubMed ID: 28805481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Cardiovascular Risk Factors in Dialysis-Dependent End Stage Kidney Disease.
    Kota H; Gohh R
    R I Med J (2013); 2021 Feb; 104(1):20-24. PubMed ID: 33517594
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease.
    Karangizi AHK; Chanouzas D; Fenton A; Moss P; Cockwell P; Ferro CJ; Harper L
    QJM; 2020 Apr; 113(4):253-257. PubMed ID: 31613364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the burden of cardiovascular disease in children with chronic kidney disease: prevention vs. damage limitation.
    Shroff R
    Pediatr Nephrol; 2021 Aug; 36(8):2537-2544. PubMed ID: 34143301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of Cardiovascular Disease During the Transition to End-Stage Renal Disease.
    Bansal N
    Semin Nephrol; 2017 Mar; 37(2):120-131. PubMed ID: 28410646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Not Available].
    Aitbaev KA; Murkamilov IT; Fomin VV
    Kardiologiia; 2019 Mar; 59(2):79-87. PubMed ID: 30853024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lipid story in chronic kidney disease: a long story with a happy end?
    Kujawa-Szewieczek A; Więcek A; Piecha G
    Int Urol Nephrol; 2013 Oct; 45(5):1273-87. PubMed ID: 23054316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ESRD-induced dyslipidemia-Should management of lipid disorders differ in dialysis patients?
    Moradi H; Streja E; Vaziri ND
    Semin Dial; 2018 Jul; 31(4):398-405. PubMed ID: 29707830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Risk Prediction in Chronic Kidney Disease.
    Li X; Lindholm B
    Am J Nephrol; 2022; 53(10):730-739. PubMed ID: 36481730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
    Streja E; Streja DA; Soohoo M; Kleine CE; Hsiung JT; Park C; Moradi H
    Semin Nephrol; 2018 Jul; 38(4):369-382. PubMed ID: 30082057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania.
    Vlad CE; Foia L; Pavel-Tanasa M; Toma V; Florea L; Voroneanu L; Apetrii M; Dodi G; Covic A
    Int Urol Nephrol; 2022 Mar; 54(3):647-659. PubMed ID: 34224064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
    Vaziri ND; Norris KC
    Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherosclerotic Vascular Disease Associated with Chronic Kidney Disease.
    Tunbridge MJ; Jardine AG
    Cardiol Clin; 2021 Aug; 39(3):403-414. PubMed ID: 34247753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.